Malta: New Drug Scheme Offers Hope to Heart Failure Patients
Heart Failure Patients in Malta to Benefit from New Drug Scheme
Imagine this: a quiet morning in Mater Dei Hospital, Dr. Joseph Mizzi, a cardiologist, is reviewing his patients’ files. He picks up Mrs. Maria’s, a 72-year-old woman living in Birkirkara, who’s been struggling with chronic heart failure. Today, he has some good news for her.
From next month, Mrs. Maria will be among the first in Malta to benefit from a new drug scheme. Sacubitril/valsartan, a medication used to treat chronic heart failure, is set to be added to the Pharmaceuticals on the Government’s Cheap list (POYC).
What is Sacubitril/valsartan and why is it significant?
Sacubitril/valsartan, sold under the brand name Entresto, is a combination of two drugs: sacubitril and valsartan. Sacubitril works by inhibiting the enzyme neprilysin, which breaks down certain hormones that help the heart pump better. Valsartan, on the other hand, is an angiotensin II receptor blocker that relaxes blood vessels.
What makes this drug significant is its potential to reduce the risk of hospitalization and death in patients with chronic heart failure. It’s been shown to improve quality of life and heart function. Until now, it’s been expensive, putting it out of reach for many Maltese patients.
How will the POYC scheme make a difference?
The POYC scheme, introduced in 2017, aims to provide affordable medication to patients with chronic conditions. By adding Sacubitril/valsartan to the list, the government is ensuring that more patients like Mrs. Maria can access this life-changing treatment.
Dr. Mizzi explains, “This is a significant step forward. We’ve seen the positive impact of this drug in clinical trials, and now we can offer it to our patients who need it most.”
According to Health Minister Chris Fearne, “This addition to the POYC scheme is part of our ongoing commitment to ensure that all Maltese citizens have access to the best possible healthcare.”
What does this mean for heart failure patients in Malta?
For patients like Mrs. Maria, this means hope. Hope for a better quality of life, hope for fewer hospital visits, and hope for a longer, healthier life. It also means peace of mind, knowing that they won’t have to choose between their health and their finances.
But this isn’t just about individual patients. It’s about the wider community. Heart failure affects around 1-2% of the general population, and that number increases with age. With an aging population, the need for affordable, effective treatments is greater than ever.
As Dr. Mizzi puts it, “This isn’t just about treating heart failure. It’s about giving our patients the chance to live their lives to the fullest.”
